Compare · MRNA vs TVGN
MRNA vs TVGN
Side-by-side comparison of Moderna Inc. (MRNA) and Tevogen Bio Holdings Inc. (TVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TVGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $61.59B, about 1319.2x TVGN ($46.7M).
- Over the past year, MRNA is up 537.5% and TVGN is down 86.0% - MRNA leads by 623.5 points.
- MRNA has been more active in the news (15 items in the past 4 weeks vs 3 for TVGN).
- MRNA has more recent analyst coverage (25 ratings vs 2 for TVGN).
- Company
- Moderna Inc.
- Tevogen Bio Holdings Inc.
- Price
- $154.14+9.79%
- $6.31-1.41%
- Market cap
- $61.59B
- $46.7M
- 1M return
- +179.70%
- -3.81%
- 1Y return
- +537.47%
- -86.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2022
- News (4w)
- 15
- 3
- Recent ratings
- 25
- 2
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest MRNA
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.85% to 67,004 units (SEC Form 4) to satisfy withholding obligation
- Moderna upgraded by Argus with a new price target
- Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
- Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
- Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
- A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity
Latest TVGN
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- SEC Form S-8 filed by Tevogen Bio Holdings Inc.
- SEC Form 10-Q filed by Tevogen Bio Holdings Inc.
- SEC Form DEF 14A filed by Tevogen Bio Holdings Inc.
- SEC Form 8-K filed by Tevogen Bio Holdings Inc.
- Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
- SEC Form PRE 14A filed by Tevogen Bio Holdings Inc.
- Tevogen Bio Announces 2026 Annual Meeting of Stockholders
- Director Sordillo Victor J. was granted 40,000 shares, increasing direct ownership by 347% to 51,539 units (SEC Form 4)
- Chief Executive Officer Saadi Ryan H. was granted 1,220,000 shares, increasing direct ownership by 49% to 3,705,689 units (SEC Form 4)